(Total Views: 494)
Posted On: 11/22/2019 1:04:35 PM
Post# of 53
Get some EVOK after pullback & ahead of NDA filing expected within days $3+ BILLION Market =1000% GEM RALLLYYYYYYYYY
EVOK = Market Cap $24 M --NDA resubmission during the Quarter -- Drug targeting $3+ BILLION market = Potential 10++BAGGER
•Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women
•Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options
•Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually
•Estimated $3-4B prescription market
•Resubmission of 505(b)(2) NDA expected Q4 2019
If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.
EVOK = Market Cap $24 M --NDA resubmission during the Quarter -- Drug targeting $3+ BILLION market = Potential 10++BAGGER
•Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women
•Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options
•Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually
•Estimated $3-4B prescription market
•Resubmission of 505(b)(2) NDA expected Q4 2019
If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.
(0)
(0)
